Literature DB >> 89855

Changes in the molecular composition of circulating hydroxyethyl starch following consecutive daily infusions in man.

J M Mishler, C R Ricketts, E J Parkhouse.   

Abstract

1 Changes in the circulating molecular composition of hydroxyethyl starch (HES) were determined in four normal men following three consecutive daily 500 ml infusions (total 1,500 ml), by passage of trichloroacetic acid filtrates of plasma through a Sepharose CL4B gel filtration column. 2 The HES recovered from the intravascular space 10 min following the injection on Days 1, 2 and 3, was of a narrower molecular size distribution than the injected material, with a noticeable shift to molecules of a low molecular weight (LMW) size. 3 The HES in the sampled plasma 24 h post-injection on Days 1, 2 and 3 consisted of molecules possessing a LMW distribution, concomitantly with a slight shift to molecules of a larger molecule size. 4 The HES recovered from the bloodstream 480 h after the third and final injection consisted of molecules possessing an intermediate size distribution, between LMW and high molecular weight (HMW) size material. 5 The results indicate that large HES molecules contained in the injected material are eliminated from the bloodstream; the HMW fraction at least partially by a alpha-amylase mediated catabolism, and the resulting LMW fraction by excretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89855      PMCID: PMC1429584          DOI: 10.1111/j.1365-2125.1979.tb00994.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Persistence of starch derivatives and dextran when infused after hemorrhage.

Authors:  W L THOMPSON; J J BRITTON; R P WALTON
Journal:  J Pharmacol Exp Ther       Date:  1962-04       Impact factor: 4.030

2.  Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander).

Authors:  T F Solanke
Journal:  Br Med J       Date:  1968-09-28

3.  A clinical physiologic study of hydroxyethyl starch.

Authors:  W Metcalf; A Papadopoulos; R Tufaro; A Barth
Journal:  Surg Gynecol Obstet       Date:  1970-08

4.  Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch.

Authors:  W L Thompson; T Fukushima; R B Rutherford; R P Walton
Journal:  Surg Gynecol Obstet       Date:  1970-11

5.  Use of hydroxyethyl starch solution in extensive surgical operations.

Authors:  S Gollub; D C Schechter; T Hirose; C P Bailey
Journal:  Surg Gynecol Obstet       Date:  1969-04

6.  Hydroxyethyl starch: an agent for hypovolemic shock treatment.

Authors:  J M Mishler; H Borberg; P M Emerson; R Gross
Journal:  J Surg Res       Date:  1977-10       Impact factor: 2.192

7.  Changes in the molecular composition of circulating hydroxyethyl starch.

Authors:  S P Farrow; M Hall; C R Ricketts
Journal:  Br J Pharmacol       Date:  1970-04       Impact factor: 8.739

8.  Hydroxyethyl starch. An agent for hypovolaemic schock treatment II. Urinary excretion in normal volunteers following three consecutive daily infusions.

Authors:  J M Mishler; H Borberg; P M Emerson; R Gross
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

  8 in total
  4 in total

1.  Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

Authors:  A C Degrémont; M Ismaïl; M Arthaud; B Oulare; O Mundler; M Paris; J F Baron
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

2.  Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

3.  Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-02       Impact factor: 3.411

Review 4.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.